Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capitol Hill BSE

This article was originally published in The Tan Sheet

Executive Summary

DSHEA inadequately protects public from mad cow disease, Public Citizen Health Research Group Deputy Director Peter Lurie, MD, asserts at Senate Commerce, Science & Transportation/Consumer Affairs Subcommittee hearing on bovine spongiform encephalopathy April 4. Due to absence of mandatory premarket review under DSHEA, "an unscrupulous manufacturer could literally take a British cow brain, crush it, dry it out, formulate it into a dietary supplement and export it to the U.S.," he says in written testimony. Lurie also referred to Walter Reed Army Medical Center researcher Scott Norton's letter in July 27 New England Journal of Medicine noting numerous supplements contain raw animal parts and therefore are "susceptible to contamination with the agents of" BSE (1"The Tan Sheet" Aug. 7, 2000, p. 17)

You may also be interested in...



BioProgress Gelatin-Free Capsules Address Vegetarian, Ethical Concerns

BioProgress Technology International's XGel Film System, the first one-piece soft capsule technology containing a cellulose base instead of gelatin, has been licensed by Peter Black Healthcare, the leading supplier of private label vitamins, minerals and herbal supplements in the U.K.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel